The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://www.proactiveinvestors.co.uk/companies/amp/news/938840?__twitter_impression=true
Morning Phil. Estimated primary completion date on clinical trials.gov is May 2021 and I believe the patients already treated will continue to be followed up according to the trial protocol. Not sure how many patients that is though and I guess no guarantee they will have to update, but it'd make sense to provide an update around that time.
Not sure if already poated...ReNeuron are taking part in this event later this month: https://www.lsegissuerservices.com/spark/edison-open-house-global-healthcare-2021
Also to note for Q2, Phase IIb stroke therapy (Pisces III) update due in May. Little talked about but potentially game-changing.
And in 2012, not much has changed! https://www.standard.co.uk/business/city-spy-reneuron-gets-on-investors-nerves-6550521.html
Perhaps MH shouldn't rush fundraising.
Sorry sent before I'd finished! I'm sure they'll rapidly assign value to exosomes once we have proof of concept. £190 million seems a bit low for everything that's going on, although the market disagrees as usual. Heading in the right direction though!
Recent analyst conference call suggested we won't get an RP update until results are announced at a conference.
Despite being open label, board would have preferred not to have had to announce results so frequently, but the low number of patients meant individual results were material.
I'd have thought they could have argued from the start that the very nature of a clinical study means there will be a gradual increase in data and that, and the length of the trial, are known features so it's only the end result that's material. But perhaps not.
A capital raise at 70p clearly is a failure for MH, giving previous pricing and competitors' fundraising abilities, there's no other way to describe it. Unless it was intentionally low, then I suppose it was a resounding success. I'd speculate that announcement of a NASDAQ listing would have bolstered the price well beyond 70p, allowing for a a sensible fundraising.
The board chose a small and heavily discounted issue on AIM over a dual listing on NASDAQ. I'd suggest that listing on NASDAQ would have boosted the price. A continued reliance on AIM does not give me confidence in the business.
The market appears to agree.
Also this article in Businessweek yesterday:
Vaccines Are Coming, But There’s No Such Hope for My Blindness ["https://www.bloomberg.com/news/articles/2020-11-25/a-covid-vaccine-is-coming-but-not-a-miracle-for-blindness-michael-schuman"]